About Steen Bjerre

This author has not yet filled in any details.
So far Steen Bjerre has created 162 blog entries.

KalVista Reports Fiscal Third Quarter Results


KalVista Pharmaceuticals, Inc. reports operational and financial results for the fiscal third quarter ended 31 January 2018. “We are pleased to have the second candidate from our oral HAE portfolio in a Phase 1 trial as we continue to pursue a best-in-class therapy,” said Andrew Crockett, CEO of KalVista. KalVista has announced the initiation of a Phase 1 [...]

CSL Behring Receives Patient Impact Award


Imagine not knowing when you might experience unpredictable, severe and painful swelling without warning in different parts of your body, including the abdomen, face, and larynx. This is what it’s like for patients with HAE who often go undiagnosed well into their adult years, ”imprisoned” by their rare disorder. Life Sciences Pennsylvania presented its 2018 [...]

BioCryst Announces Initiation of Phase 3 APeX-2 Trial


BioCryst Pharmaceuticals, Inc. announces the dosing of the first patient into APeX-2, a Phase 3 clinical trial evaluating two dosage strengths of BCX7353 administered orally once-daily (QD)  as a preventive treatment to reduce the frequency of attacks in patients with HAE. “The ability to safely prevent attacks of angioedema with an oral medicine has been [...]

CSL’s CEO on Industry to Improve Patients’ Access to Medicines


In a keynote address on patients’ access to medicines at the eyeforpharma Barcelona summit, CSL Behring CEO and Managing Director Paul Perreault told fellow biotech industry leaders that access to life-saving medicines remains a global challenge that cannot be ignored. “Our role in ensuring patients have access to these medicines is an imperative, not an [...]

Pharming’s Preliminary Financial Results for 2017


At the presentation of the Pharming Group N.V. preliminary (unaudited) financial report for the full year ended 31 December 2017 CEO Sijmen de Vries said: "The remarkable growth reported in 2017 was a direct result of our strategic decisions to reacquire the commercial rights to Ruconest in North America and implement direct marketing in the major [...]

Adverum Reports Fourth Quarter 2017 Financial Results


From the Adverum Biotechnologies, Inc. financial results for the fourth quarter ended 31 December 2017 and corporate update: “We enter 2018 with significant momentum following a year of critical execution to transform Adverum into a clinical-stage company,” said Amber Salzman, Ph.D., President and CEO. “We plan to submit an Investigational New Drug Application with the [...]

Sobi launches enhanced corporate sustainability initiative


Swedish Orphan Biovitrum AB (Sobi) announces the launch of an enhanced corporate sustainability programme with a strong connection to the company’s strategy of providing sustainable access to treatments for rare diseases. As part of the new sustainability strategy, Sobi has identified several focus areas that are important for both the stakeholder communities and Sobi’s business. [...]

BioCryst reports full year financial results


At the announcement of the BioCryst Pharmaceuticals, Inc.  financial results for 2017 President & CEO Jon P. Stonehouse said: “Our team made significant progress in 2017 and we are off to a strong start in 2018. We are keenly focused on continuing that momentum by advancing our pipeline, adding additional programs and driving our BCX7353 oral [...]

First patient dosed in APeX-S trial


BioCryst Pharmaceuticals, Inc. has dosed the first patient in APeX-S, a long-term safety trial evaluating two dosage strengths of BCX7353 administered orally once-daily as a preventive treatment in patients with HAE. “Initiation of the APeX-S trial is an important milestone to support filing and approval of BCX7353, and furthers our core strategy of bringing a [...]

EMA grants accelerated assessment for Lanadelumab


The European Medicines Agency (EMA) has granted an accelerated assessment for Lanadelumab (SHP643), an investigational treatment being evaluated for the prevention of angioedema attacks in patients 12 years and older with HAE. “The EMA decision, coupled with the U.S. FDA’s recent Priority Review designation for Lanadelumab, reinforces Shire’s dedication to advancing new treatment options for [...]